Skip to main content
Top
Published in: Inflammation 4-6/2005

01-12-2005

Inhibition of Prostaglandin \({\text{F}}_{{{\text{2}}\alpha }} \) by Selective Cyclooxygenase 2 Inhibitors Accounts for Reduced Rat Leukocyte Migration

Authors: Gustavo Batista de Menezes, Webster Glayser Pimenta dos Reis, Júlia Maria Moreira Santos, Igor Dimitri Gama Duarte, Janetti Nogueira de Francischi

Published in: Inflammation | Issue 4-6/2005

Login to get access

Abstract

To investigate whether selective COX 2 inhibitors (celecoxib, rofecoxib) would play a role in a model of leukocyte migration in rats. Bacterial endotoxin (Escherichia coli LPS) was intraperitoneally injected at time zero in rats that were previously treated with unspecific and selective cyclooxygenase inhibitors. LPS induced a dose and time-dependent increase in leukocyte number, which was predominantly related to the presence of PMN neutrophils. Only rats treated with selective COX 2 inhibitors and indomethacin showed a significant reduction in leukocyte numbers following LPS administration. Prostaglandins E2 and \( {\text{F}}_{{2\alpha }} \) were injected into the peritoneum and the chemoatractant effect was studied. Only \( {\text{PGF}}_{{2\alpha }} \) was able to induce neutrophil increase following injection. Intraperitoneal reposition of \( {\text{PGF}}_{{2\alpha }} \) restored the abrogated leukocyte response to LPS, shown by rats pretreated with rofecoxib. It can be concluded that COX 2, through \( {\text{PGF}}_{{2\alpha }} \) release, is the isoform responsible for neutrophil recruitment in the rat model of LPS-induced inflammation.
Literature
1.
go back to reference Hellewell, P. G., and P. M. Henson. 1991. Mechanisms of granulocyte accumulation and emigration in vivo. In: Vascular Endothelium: Interactions with Circulating Cells, Gordon ed. Elsevier, Amsterdam, pp. 143–160. Hellewell, P. G., and P. M. Henson. 1991. Mechanisms of granulocyte accumulation and emigration in vivo. In: Vascular Endothelium: Interactions with Circulating Cells, Gordon ed. Elsevier, Amsterdam, pp. 143–160.
2.
go back to reference Lin, T. J., R. Garduno, R. T. M. Boudreau, and A. C. Issekutz. 2002. Pseudomonas aeruginosa activates human mast cells to induce neutrophil transendothelial migration via mast cell-derived IL-1 alpha and beta. J. Immunol. 169:4522–4530.PubMed Lin, T. J., R. Garduno, R. T. M. Boudreau, and A. C. Issekutz. 2002. Pseudomonas aeruginosa activates human mast cells to induce neutrophil transendothelial migration via mast cell-derived IL-1 alpha and beta. J. Immunol. 169:4522–4530.PubMed
3.
go back to reference Arnould, T., R. Thibaut-Vercruyssen, N. Bouaziz, M. Dieu, J. Remacie, and C. Michiels. 2001. \( {\text{PGF}}_{{2\alpha }} \), a prostanoid released by endothelial cells activated by hypoxia, is a chemoattractant candidate for neutrophil recruitment. Am. J. Pathol. 159(1):345–357.PubMed Arnould, T., R. Thibaut-Vercruyssen, N. Bouaziz, M. Dieu, J. Remacie, and C. Michiels. 2001. \( {\text{PGF}}_{{2\alpha }} \), a prostanoid released by endothelial cells activated by hypoxia, is a chemoattractant candidate for neutrophil recruitment. Am. J. Pathol. 159(1):345–357.PubMed
4.
go back to reference Lee, W., S. Aitken, J. Sodek, and C. A. McCulloch. 1995. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzyme in human periodontitis. J. Periodontal. Res. 30:23–33.PubMedCrossRef Lee, W., S. Aitken, J. Sodek, and C. A. McCulloch. 1995. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzyme in human periodontitis. J. Periodontal. Res. 30:23–33.PubMedCrossRef
5.
go back to reference Chan, C. C., S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, et al. 1999. Rofecoxib (Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2- (5H)-furanone): a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and Biochemical profiles. J. Pharmacol. Exp. Ther. 290:551–560.PubMed Chan, C. C., S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, et al. 1999. Rofecoxib (Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2- (5H)-furanone): a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and Biochemical profiles. J. Pharmacol. Exp. Ther. 290:551–560.PubMed
6.
go back to reference Penning, T. B., J. J. Talley, S. R. Bertenshaw, J. S. Carter, P. W. Collins, S. Docter, et al. 1997. Synthesis and biological evaluation of the 1,5-Diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-y1) benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 40:1347–1365.PubMedCrossRef Penning, T. B., J. J. Talley, S. R. Bertenshaw, J. S. Carter, P. W. Collins, S. Docter, et al. 1997. Synthesis and biological evaluation of the 1,5-Diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-y1) benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 40:1347–1365.PubMedCrossRef
7.
go back to reference Kuritz, L., and A. Weaver. 2003. Advances in rheumatology: coxibs and beyond. J. Pain. Symp. Manage. 25S:S6–S20.CrossRef Kuritz, L., and A. Weaver. 2003. Advances in rheumatology: coxibs and beyond. J. Pain. Symp. Manage. 25S:S6–S20.CrossRef
8.
go back to reference Whittle, B. J. R. 2003. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam. Clin. Pharmacol. 17:301–313.PubMedCrossRef Whittle, B. J. R. 2003. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam. Clin. Pharmacol. 17:301–313.PubMedCrossRef
9.
go back to reference Vane, J. R., Y. S. Bakhle, and R. M. Botting. 1998. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:97–120.PubMedCrossRef Vane, J. R., Y. S. Bakhle, and R. M. Botting. 1998. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:97–120.PubMedCrossRef
10.
go back to reference Francischi, J. N., C. T. Chaves, A. C. L. Moura, A. S. Lima, D. L. Ferreira-Alves, A. O. Rocha, et al. 2002. Selective inhibitors of cyclooxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br. J. Pharmacol. 137(6):837–844.PubMedCrossRef Francischi, J. N., C. T. Chaves, A. C. L. Moura, A. S. Lima, D. L. Ferreira-Alves, A. O. Rocha, et al. 2002. Selective inhibitors of cyclooxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br. J. Pharmacol. 137(6):837–844.PubMedCrossRef
11.
go back to reference Déciga-Campos, M., and F. J. López-Muñoz. 2004. Participation of the L-arginine-nitric oxide-cyclic GMP-ATP-sensitive K+ channel cascade in the antinociceptive effect of rofecoxib. Eur. J. Pharmacol. 484:193–199.PubMedCrossRef Déciga-Campos, M., and F. J. López-Muñoz. 2004. Participation of the L-arginine-nitric oxide-cyclic GMP-ATP-sensitive K+ channel cascade in the antinociceptive effect of rofecoxib. Eur. J. Pharmacol. 484:193–199.PubMedCrossRef
12.
go back to reference Allcock, G. H., M. Allegra, R. J. Flower, and M. Perreti. 2001. Neutrophil accumulation induced by bacterial lipopolysaccharide: effects of dexamethasone and annexin 1. Clin. Exp. Invest. 123(1):62–67. Allcock, G. H., M. Allegra, R. J. Flower, and M. Perreti. 2001. Neutrophil accumulation induced by bacterial lipopolysaccharide: effects of dexamethasone and annexin 1. Clin. Exp. Invest. 123(1):62–67.
13.
go back to reference Muller, W. A. 2002. Leukocyte-endothelial cell interactions in the inflammatory response. Lab. Invest. 82(5):521–533.PubMedCrossRef Muller, W. A. 2002. Leukocyte-endothelial cell interactions in the inflammatory response. Lab. Invest. 82(5):521–533.PubMedCrossRef
14.
go back to reference Smith, C. J., Y. Zhang, C. M. Koboldt, J. Muhammad, B. S. Zweifel, A. Shaffer, et al. 1998. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA 95:13313–13318.PubMedCrossRef Smith, C. J., Y. Zhang, C. M. Koboldt, J. Muhammad, B. S. Zweifel, A. Shaffer, et al. 1998. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA 95:13313–13318.PubMedCrossRef
15.
go back to reference Vane, J. R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nat. New. Biol. 231:232–235.PubMed Vane, J. R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nat. New. Biol. 231:232–235.PubMed
16.
go back to reference Sachs, D., F. Q. Cunha, S. H. Ferreira. 2004. Peripheral analgesic blockade of hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway. Proc. Natl. Acad. Sci. USA 101(10):3680–3685.PubMedCrossRef Sachs, D., F. Q. Cunha, S. H. Ferreira. 2004. Peripheral analgesic blockade of hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway. Proc. Natl. Acad. Sci. USA 101(10):3680–3685.PubMedCrossRef
17.
go back to reference Ivanov, A. I., and A. A. Romanovsky. 1977. Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Front Biosci. 9:1977–1993. Ivanov, A. I., and A. A. Romanovsky. 1977. Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Front Biosci. 9:1977–1993.
18.
go back to reference Aronoff, D. M., and E. G. Neilson. 2001. Antipyretics: mechanisms of action and clinical use in fever suppression. Am. J. Med. 111:304–315.PubMedCrossRef Aronoff, D. M., and E. G. Neilson. 2001. Antipyretics: mechanisms of action and clinical use in fever suppression. Am. J. Med. 111:304–315.PubMedCrossRef
19.
go back to reference Menezes, G. B., K. L. M. Maltos, J. M. M. Santos, I. D. G. Duarte, and J. N. Francischi. 2003. Cyclooxygenase (COX)-2 isoform accounts for neutrophil migration in a model of leukocyte recruitment induced by bacterial lipopolyssacaride in rats. Inflamm. Res. 52:S88. Menezes, G. B., K. L. M. Maltos, J. M. M. Santos, I. D. G. Duarte, and J. N. Francischi. 2003. Cyclooxygenase (COX)-2 isoform accounts for neutrophil migration in a model of leukocyte recruitment induced by bacterial lipopolyssacaride in rats. Inflamm. Res. 52:S88.
20.
go back to reference Pereira, L. S. M., D. L. Ferreira-Alves, M. A. Resende, V. A. Romualdo, W. G. P. Reis, M. T. P. Lopes, et al. 2003. Reduced production of hyperalgesic substances by mononuclear cells from aged rats incubated with carrageenan: role of interleukin-2 and prostaglandins. Inflamm. Res. 52(3):119–125.PubMedCrossRef Pereira, L. S. M., D. L. Ferreira-Alves, M. A. Resende, V. A. Romualdo, W. G. P. Reis, M. T. P. Lopes, et al. 2003. Reduced production of hyperalgesic substances by mononuclear cells from aged rats incubated with carrageenan: role of interleukin-2 and prostaglandins. Inflamm. Res. 52(3):119–125.PubMedCrossRef
21.
go back to reference Giuliano, F., and T. D. Warner. 2002. Origins of prostaglandin E2: Involvements of cyclooxygenase (COX)-1 and COX 2 in human and rat systems. J. Pharmacol. Exp. Ther. 303:1001–1006.PubMedCrossRef Giuliano, F., and T. D. Warner. 2002. Origins of prostaglandin E2: Involvements of cyclooxygenase (COX)-1 and COX 2 in human and rat systems. J. Pharmacol. Exp. Ther. 303:1001–1006.PubMedCrossRef
22.
go back to reference Lauffenburger, D. A., and A. F. Horwitz. 1996. Cell migration: a physically integrated molecular process. Cell 84(3):359–369.PubMedCrossRef Lauffenburger, D. A., and A. F. Horwitz. 1996. Cell migration: a physically integrated molecular process. Cell 84(3):359–369.PubMedCrossRef
23.
go back to reference Vane, J. R., and R. M. Botting. 1997. Mechanism of action of aspirin-like drugs. Semin. Arthritis. Rheum. 26:2–10.PubMedCrossRef Vane, J. R., and R. M. Botting. 1997. Mechanism of action of aspirin-like drugs. Semin. Arthritis. Rheum. 26:2–10.PubMedCrossRef
24.
go back to reference Warner, T. D., I. Vojnovic, F. Giuliano, R. Jiménez, D. Bishop-Bailey, and J. A. Mitchell. 2004. Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. J. Pharmacol. Exp. Ther. 310:642–647.PubMedCrossRef Warner, T. D., I. Vojnovic, F. Giuliano, R. Jiménez, D. Bishop-Bailey, and J. A. Mitchell. 2004. Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. J. Pharmacol. Exp. Ther. 310:642–647.PubMedCrossRef
25.
go back to reference Foster, S. J., M. E. McCormick, A. Howart, and D. Aked. 1986. Leukocyte recruitment in the subcutaneous sponge implant model of acute inflammation in rat is not mediated by leukotriene B4. Biochem. Pharmacol. 35:1709–1717.PubMedCrossRef Foster, S. J., M. E. McCormick, A. Howart, and D. Aked. 1986. Leukocyte recruitment in the subcutaneous sponge implant model of acute inflammation in rat is not mediated by leukotriene B4. Biochem. Pharmacol. 35:1709–1717.PubMedCrossRef
26.
go back to reference Ockilnd, A., S. Lake, K. Krook, I. Hallin, M. Nistér, and B. Westermark. 1997. Localization of the prostaglandin F2 alpha on rat tissues. Prostaglandins, Leukot. Essent. Fat. Acids. 57:6527–6532. Ockilnd, A., S. Lake, K. Krook, I. Hallin, M. Nistér, and B. Westermark. 1997. Localization of the prostaglandin F2 alpha on rat tissues. Prostaglandins, Leukot. Essent. Fat. Acids. 57:6527–6532.
27.
go back to reference Kammerl, M. C., J. Debler, G. A. Riegger, and B. K. Kramer. 2004. COX 2 inhibitors and risk of heart failure. Lancet. 364:1486–1487.PubMedCrossRef Kammerl, M. C., J. Debler, G. A. Riegger, and B. K. Kramer. 2004. COX 2 inhibitors and risk of heart failure. Lancet. 364:1486–1487.PubMedCrossRef
28.
go back to reference Topol, E. J. 2004. Failing the Public Health—Rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351:1707–1709.PubMedCrossRef Topol, E. J. 2004. Failing the Public Health—Rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351:1707–1709.PubMedCrossRef
Metadata
Title
Inhibition of Prostaglandin by Selective Cyclooxygenase 2 Inhibitors Accounts for Reduced Rat Leukocyte Migration
Authors
Gustavo Batista de Menezes
Webster Glayser Pimenta dos Reis
Júlia Maria Moreira Santos
Igor Dimitri Gama Duarte
Janetti Nogueira de Francischi
Publication date
01-12-2005
Published in
Inflammation / Issue 4-6/2005
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-006-9013-z

Other articles of this Issue 4-6/2005

Inflammation 4-6/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.